SULFADIAZINE

Post-LOE

sulfadiazine

AbbVie

ANDAORALTABLET

Approved

Jul 1994

Lifecycle

Post-LOE

Competitive Pressure

30/100

Clinical Trials

Data completeness

3/8 — Basic

Drug data last refreshed 18h ago

$0.0BPart D

Mechanism of Action

Pharmacologic Class:

Sulfonamide Antibacterial

Indications

Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.

Clinical Trials (2)

NCT00004317Phase 4Recruiting

Pyrimethamine, Sulfadiazine, and Leucovorin in Treating Patients With Congenital Toxoplasmosis

Started Jul 2000

600 enrolled

Toxoplasmosis

NCT00000794Phase 2Completed

Phase II Randomized Open-Label Trial of Atovaquone Plus Pyrimethamine and Atovaquone Plus Sulfadiazine for the Treatment of Acute Toxoplasmic Encephalitis

100 enrolled

Toxoplasmosis, CerebralHIV Infections

Company

Worked on SULFADIAZINE at AbbVie? Share your interview experience or compensation data (+7 days Pro)

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.